TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14507259

Group type: EXPERIMENTAL
Intervention: Creatine loading (20 g.day(‐1) for 5 days, followed by 2 g.day(‐1) for 37 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11324324

Group type: EXPERIMENTAL
Intervention: Transmyocardial Laser Revascularization (TMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angioplasty and coronary artery bypass grafts
Number of subjects: 0
Study: 9552772

Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (90 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine (25 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (60 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 7914960

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted red cells
Number of subjects: 871

Group type: COMPARATOR
Intervention: Packed cells without buffy coat
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Any blood transfusion
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 871
Study: 3288533

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study: 28278742

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 115
Study: 21745127

Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (Control Group)
Number of subjects: 100
Study: 22434919

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) plus Cognitive Behavioral Therapy (CBT)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 344
Study: 20478449

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19213342

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied on acupoints Zhongliao (BL33) and Huiyang (BL35), for 30 min, once every two days for 4 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Terazosin 2 mg taken orally once every evening for 4 weeks
Number of subjects: 93
Study: 15671224

Group type: EXPERIMENTAL
Intervention: Daily iron (125 mg FeSO4, 10 microg folate, 25 mg vitamin C)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (10 microg folate and 25 mg vitamin C)
Number of subjects: 81
Study: 12627414

Group type: EXPERIMENTAL
Intervention: Blinded sample size reassessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fixed sample size design
Number of subjects: 0
Study: 10553500

Group type: EXPERIMENTAL
Intervention: RAGE GLY82SER variant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA class II haplotypes DRB1*0401-DQA1*0301-DQB1*0301
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA class II haplotypes DRB1*1501-DQA1*0102-DQB1*0602
Number of subjects: 0
Study: 8932539

Group type: EXPERIMENTAL
Intervention: AC137 30-mug bolus dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC137 100-mug bolus dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC137 300-mug bolus dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC137 30-mug infusion dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC137 100-mug infusion dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC137 300-mug infusion dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1763292

Group type: EXPERIMENTAL
Intervention: Budesonide 1 mg/100 ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Budesonide 2 mg/100 ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Budesonide 4 mg/100 ml
Number of subjects: 146

Group type: COMPARATOR
Intervention: Prednisolone 25 mg/100 ml
Number of subjects: 146
Study: 7045360

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 99
Study: 31707153

Group type: EXPERIMENTAL
Intervention: Villalta scale for diagnosing PTS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Villalta scale only
Number of subjects: 88

Group type: COMPARATOR
Intervention: Clinical criteria only
Number of subjects: 88
Study: 29159755

Group type: EXPERIMENTAL
Intervention: Pedophilic orientation with extrinsic non-offending motivation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Pedophilic orientation with intrinsic non-offending motivation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Teleiophilic orientation with extrinsic non-offending motivation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Teleiophilic orientation with intrinsic non-offending motivation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Disgust
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Fear
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Disgust, fear, and anger
Number of subjects: 205
Study: 26979470

Group type: EXPERIMENTAL
Intervention: Daily physical activities (DA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inactivity (IA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heavy resistance exercise (RE)
Number of subjects: 24
Study: 24739896

Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg once every 2 weeks)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Cetuximab (initial dose 400 mg/m2; 250 mg/m2 once a week thereafter)
Number of subjects: 1010
Study: 23216943

Group type: EXPERIMENTAL
Intervention: Treatment with etanercept and standardized HRQoL assessment and communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment with etanercept alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRQoL intervention (Skindex-29 assessment)
Number of subjects: 0
Study: 20625364

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10-30 mg/9 hours
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo transdermal system (PTS)
Number of subjects: 217
Study: 17561494

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tilt training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 15050334

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Historical normal controls
Number of subjects: 15
Study: 12492613

Group type: EXPERIMENTAL
Intervention: Quinine sulphate (600 mg) alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Quinine sulphate (600 mg) plus troleandomycin (TAO; 500 mg every 8 h)
Number of subjects: 10
Study: 9475328

Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8565711

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-thrombolysis group
Number of subjects: 37
Study: 2798924

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 30766

Group type: EXPERIMENTAL
Intervention: Lorazepam (3 mg/day: 2 mg in the evening and 1 mg in the morning)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31514233

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg/d for 10 days, then 50 mg/d for 10 days, and 25 mg/d for 10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone (0.4 mg/kg/d for 15 days, then 0.2 mg/kg/d for 15 days)
Number of subjects: 60
Study: 30992033

Group type: EXPERIMENTAL
Intervention: Active TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active TENS + Patient education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo TENS + Patient education
Number of subjects: 80
Study: 29251976

Group type: EXPERIMENTAL
Intervention: 15.8 mg/g Spectrum cigarette
Number of subjects: 26

Group type: COMPARATOR
Intervention: 5.2 mg/g Spectrum cigarette
Number of subjects: 26

Group type: COMPARATOR
Intervention: 2.4 mg/g Spectrum cigarette
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.4 mg/g Spectrum cigarette
Number of subjects: 26
Study: 26236924

Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Entecavir (0.5 mg/d)
Number of subjects: 120
Study: 23596887

Group type: EXPERIMENTAL
Intervention: Activating renal blood circulation and ovarian stimulation formula
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 86
Study: 21502457

Group type: EXPERIMENTAL
Intervention: 80% oxygen during anesthesia, followed by high‐flow oxygen for 2 hours in the recovery room
Number of subjects: 210

Group type: COMPARATOR
Intervention: 30% oxygen, as usual
Number of subjects: 210
Study: 19653763

Group type: EXPERIMENTAL
Intervention: Audio-visual stimulus pairs presented at various relative delays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audio-visual stimulus pairs with physical synchrony as a standard
Number of subjects: 0
Study: 16998208

Group type: EXPERIMENTAL
Intervention: TREAT (computerized decision support system)
Number of subjects: 2326

Group type: COMPARATOR
Intervention: Physician's treatment (control)
Number of subjects: 2326
Study: 15585610

Group type: EXPERIMENTAL
Intervention: Iodine I 131 Tositumomab
Number of subjects: 78

Group type: COMPARATOR
Intervention: unlabeled Tositumomab
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Iodine I 131 Tositumomab (crossover)
Number of subjects: 78

Group type: COMPARATOR
Intervention: unlabeled Tositumomab (prior response)
Number of subjects: 78
Study: 11740759

Group type: EXPERIMENTAL
Intervention: Adjusted low-dose warfarin (INR 1.4-1.8)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (2 mg daily)
Number of subjects: 245
Study: 9284597

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10
Study: 8453847

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone (750 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin with didanosine-placebo
Number of subjects: 12
Study: 3535814

Group type: EXPERIMENTAL
Intervention: 1000 mg deoxycholic acid
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31892654

Group type: EXPERIMENTAL
Intervention: Hunger Training (HT)
Number of subjects: 40
Study: 29097257

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 26467988

Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 19
Study: 25229980

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg · kg(‐1) OM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 μg · kg(‐1) IND)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (oral honey and intranasal saline)
Number of subjects: 52
Study: 22369914

Group type: EXPERIMENTAL
Intervention: Baseline LA volume (20.5±5.9 mL/m2)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: High LA volumes at baseline
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Peak creatine kinase concentration
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Higher LA volumes at baseline
Number of subjects: 246
Study: 18540006

Group type: EXPERIMENTAL
Intervention: Training of lay health influencers in brief interventions for tobacco cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of material resources to health influencers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creation of a 'community of practice' among health influencers
Number of subjects: 0
Study: 18677241

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lubricant 1 (low viscosity)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lubricant 2 (high viscosity)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No lubricant (baseline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with lubricants
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low Dk lenses with lubricants
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low Dk lenses with saline
Number of subjects: 15
Study: 16431379

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (one pill)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (two pills)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (both dosages)
Number of subjects: 0
Study: 12817910

Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 33
Study: 12845759

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times a day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times a day
Number of subjects: 28
Study: 9216948

Group type: EXPERIMENTAL
Intervention: Helium-oxygen (HeO2) breathing during exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airway Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline inhalation (Control)
Number of subjects: 0
Study: 8354045

Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoclopramide-dimethicone combination
Number of subjects: 30
Study: 3716912

Group type: EXPERIMENTAL
Intervention: Small, medium, and large puff instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled puff duration
Number of subjects: 0
Study: 29605522

Group type: EXPERIMENTAL
Intervention: Home-based lower limb exercise intervention
Number of subjects: 576

Group type: COMPARATOR
Intervention: Home-based upper limb exercise intervention
Number of subjects: 576
Study: 29178746

Group type: EXPERIMENTAL
Intervention: Power toothbrush (Oral-B Professional Care 7000)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Manual toothbrush (Lion Dentor Systema)
Number of subjects: 123
Study: 23688422

Group type: EXPERIMENTAL
Intervention: 1000 μg fluticasone propionate (FP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 47
Study: 23513282

Group type: EXPERIMENTAL
Intervention: Heavy exercise (dual cycle ergometry) during a 2-hour oxygen prebreathe (F1O2 - 1.0)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Light arm exercise
Number of subjects: 13
Study: 20651220

Group type: EXPERIMENTAL
Intervention: High saturated fat diet with exercise (SE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet with exercise (UE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High saturated fat diet with sedentary condition (SS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High monounsaturated fat diet with sedentary condition (US)
Number of subjects: 8
Study: 18512087

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 40
Study: 16614585

Group type: EXPERIMENTAL
Intervention: Cessation of douching for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuation of douching
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comparison of vaginal flora between groups
Number of subjects: 48
Study: 14649610

Group type: EXPERIMENTAL
Intervention: Midazolam alone (Group A: 1 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam plus meperidine (Group B: 0.5 and 1 mg/kg)
Number of subjects: 20
Study: 10879380

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 40
Study: 8774204

Group type: EXPERIMENTAL
Intervention: Standard intravenous heparin protocol
Number of subjects: 199
Study: 30318751

Group type: EXPERIMENTAL
Intervention: Dasatinib, Nilotinib, or Ponatinib (frontline TKI therapy)
Number of subjects: 219
Study: 27378231

Group type: EXPERIMENTAL
Intervention: Arabin pessary
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard Arm (control)
Number of subjects: 700
Study: 23407378

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 gm)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intravenous dexketoprofen (50 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 137
Study: 23035005

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 39
Study: 21992890

Group type: EXPERIMENTAL
Intervention: Intermittent neuromuscular electrical stimulation applied to the right quadriceps muscle for 30 minutes daily.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-stimulated limb).
Number of subjects: 0
Study: 18028530

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 16144892

Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 8 g/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metformin, 2 g/d
Number of subjects: 39
Study: 12696778

Group type: EXPERIMENTAL
Intervention: Non-invasive tibial nerve stimulation (Group I)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral oxybutynin 5 mg t.i.d. (Group II)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (Group III)
Number of subjects: 28
Study: 9894548

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) used daily for 3 or 6 months
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 204
Study: 7570436

Group type: EXPERIMENTAL
Intervention: Asthma self-management programme based on home peak flow monitoring and surgery review by a general practitioner or practice nurse
Number of subjects: 72

Group type: COMPARATOR
Intervention: Planned visits for surgery review only
Number of subjects: 72
Study: 2197335

Group type: EXPERIMENTAL
Intervention: Avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 7423160

Group type: EXPERIMENTAL
Intervention: 3 daily doses of 220 mg zinc sulfate (group B)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No zinc therapy (group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Zinc substitution in low zinc group B
Number of subjects: 91

Group type: COMPARATOR
Intervention: Initial ulcer areas in patients with higher serum zinc levels (group A)
Number of subjects: 91
Study: 31569307

Group type: EXPERIMENTAL
Intervention: Future-oriented message with gain framing
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Future-oriented message with loss framing
Number of subjects: 195

Group type: COMPARATOR
Intervention: Present-oriented message with gain framing
Number of subjects: 195

Group type: COMPARATOR
Intervention: Present-oriented message with loss framing
Number of subjects: 195
Study: 30819765

Group type: EXPERIMENTAL
Intervention: Bevacizumab + radiation therapy + temozolomide
Number of subjects: 116

Group type: COMPARATOR
Intervention: Radiation therapy + temozolomide
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Multimodal imaging (diffusion, perfusion, spectroscopy)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Multimodal imaging
Number of subjects: 116
Study: 28039050

Group type: EXPERIMENTAL
Intervention: HCG administration (250 IU intramuscularly 3 times per week for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HCG administration
Number of subjects: 30
Study: 26390998

Group type: EXPERIMENTAL
Intervention: Interactive web-based program (Healthy Heart Profile)
Number of subjects: 160
Study: 23566033

Group type: EXPERIMENTAL
Intervention: Oral sucrose (group A)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Wrapping (group B)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Skin conductance variations
Number of subjects: 158
Study: 21392619

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Optimal medical therapy (MED)
Number of subjects: 124
Study: 19479161

Group type: EXPERIMENTAL
Intervention: Tango
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Waltz/Foxtrot
Number of subjects: 58

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 58
Study: 17090165

Group type: EXPERIMENTAL
Intervention: Laceback ligatures
Number of subjects: 15

Group type: COMPARATOR
Intervention: Superelastic NiTi closed coil springs
Number of subjects: 15
Study: 14687015

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) 200 U
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) twice injected
Number of subjects: 60
Study: 11378317

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 144
Study: 9226739

Group type: EXPERIMENTAL
Intervention: 40 mg idazoxan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7516372

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Finasteride (both dosages)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600